Methylphenidate and Response to Alcohol Cues
ConditionAlcohol Use Disorder
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-25
SponsorUniversity of Florida
About this trial
The purpose of this study is to determine whether changes in attention levels related to taking a single dose of a medication called methylphenidate, also known as Ritalin, affects responses to alcohol cues. The study will observe the effects of methylphenidate or a placebo on neural and craving responses to alcohol cues through fMRI and behavioral testing. Participants will be involved in one remote and two in-person sessions.
Eligibility criteria
Qualifiers
Adults ages 18-25 years
Meets DSM-5 criteria for Alcohol Use Disorder -OR- score on the Alcohol Use Disorders Identification Test (AUDIT) of >=8
Fluent in English
Normal or corrected to normal vision
Disqualifiers
Meets DSM-5 criteria for psychotic disorders, neurological disorders, or substance use disorders other than Alcohol Use Disorder.
Participant routinely uses psychoactive drugs or medications except for non-dependent marijuana or nicotine use (due to common use of these substances in individuals with Alcohol Use Disorder).
Participant has contraindications for taking methylphenidate.
Participant has contraindications for being in an MRI machine
Trial design
Treatments tested in this trial
- Methylphenidate Pill
- Placebo Pill
Treatment groups
50 Participants
are divided into 2 treatment groupsSponsors and collaborators
University of Florida
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Collaborator
Source ClinicalTrials.gov